NCT04231513View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

E2814

E2814, intravenous infusion.

DRUG

E2814-matched placebo

E2814-matched placebo, intravenous infusion.

Trial Locations (2)

78217

Worldwide Clinical Trials, San Antonio

91206

California Clinical Trials Medical Group/Parexel International, Glendale

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT04231513 - A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants | Biotech Hunter | Biotech Hunter